Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $264.36M
• Dividend Yield: N/A
• Average Volume (3M): 200.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: -71.42%
• EPS Growth: -248.91%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.06
• Shares Outstanding: 38,037,080
• 10 Day Avg. Volume: 242,257
• 30 Day Avg. Volume: 200,817
• PEG Ratio: -0.01
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 3.06
• P/FCF Ratio: -14.43
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $16.50
• Price Target Upside: 138.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $7.50 ▲(8.54% Upside)

Entrada Therapeutics Inc. faces significant financial challenges, particularly in revenue generation and profitability, which heavily impacts its overall score. Technical analysis shows positive momentum, but potential overbought conditions could limit further gains. Valuation remains a concern with a negative P/E ratio, reflecting ongoing profitability issues.

Positive Factors

Proprietary Technology

Entrada's TET platform is a key competitive advantage, enabling the development of unique therapies that can effectively deliver therapeutic agents directly into cells, potentially leading to breakthrough treatments for genetic and rare disorders.

Partnerships and Collaborations

Strategic partnerships enhance Entrada's research capabilities and provide financial support through milestone payments and royalties, which are crucial for sustaining long-term growth and innovation in the biopharmaceutical sector.

Revenue Potential

Entrada's ability to secure funding from diverse sources, including government and non-profits, underscores its potential to advance drug candidates and attract further investments, bolstering its long-term revenue prospects.

Negative Factors

Revenue Decline

A significant decline in revenue indicates challenges in maintaining sales momentum, which could hinder the company's ability to invest in R&D and sustain its competitive position over the long term.

Profitability Challenges

Persistent negative margins reflect difficulties in achieving profitability, which may limit Entrada's capacity to reinvest in its business and impact its financial stability in the medium to long term.

Cash Flow Issues

Negative cash flow highlights challenges in generating sufficient cash to fund operations and growth initiatives, potentially constraining Entrada's ability to execute its strategic objectives effectively.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics Inc (TRDA) is a biotechnology company focused on developing transformative therapies for patients with serious diseases, particularly in the field of genetic and rare disorders. The company utilizes its proprietary Transduction Enabled Therapeutics (TET) platform to create drug candidates that can effectively deliver therapeutic agents directly into cells, thereby addressing the underlying causes of diseases. Entrada operates primarily in the biopharmaceutical sector, with a commitment to advancing innovative treatments that leverage its unique technology for improved patient outcomes.

How the Company Makes Money

Entrada Therapeutics generates revenue through a combination of product development partnerships, grants, and potential future product sales. The company collaborates with pharmaceutical firms and research organizations to develop its therapies, often receiving milestone payments and royalties from these partnerships. Additionally, Entrada may receive funding from government and non-profit organizations aimed at supporting research in rare and genetic diseases. As the company advances its drug candidates through clinical trials, it may also attract further investments and partnerships, enhancing its revenue potential.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Entrada Therapeutics Inc. faces significant financial challenges, particularly in revenue generation and profitability. The income statement shows a sharp decline in revenue and negative margins. The balance sheet indicates moderate leverage but inefficiencies in generating returns. Cash flow issues persist despite some improvement in free cash flow.

Income Statement

Entrada Therapeutics Inc. has experienced significant volatility in its revenue and profitability. The TTM data shows a sharp decline in revenue by 53.85%, with negative net and EBIT margins indicating ongoing losses. Despite a strong gross profit margin, the company struggles with profitability, as evidenced by negative net profit and EBIT margins.

Balance Sheet

The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.14, indicating manageable debt levels. However, the company has a negative return on equity, suggesting inefficiencies in generating returns for shareholders. The equity ratio is stable, showing a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals challenges in cash generation, with negative operating cash flow and free cash flow. The free cash flow growth rate is positive, but the operating cash flow to net income ratio is negative, indicating cash flow issues despite some improvement in free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.52M	210.78M	129.01M	0.00	0.00	0.00
Gross Profit	58.91M	210.78M	129.01M	0.00	0.00	-326.00K
EBITDA	-118.58M	47.01M	-321.00K	-95.35M	-50.01M	-26.34M
Net Income	-103.45M	65.63M	-6.68M	-94.62M	-51.16M	-26.38M
Balance Sheet
Total Assets	412.90M	526.32M	469.19M	252.06M	305.83M	43.53M
Cash, Cash Equivalents and Short-Term Investments	326.84M	420.00M	351.97M	188.71M	291.06M	39.05M
Total Debt	52.40M	59.21M	68.23M	25.94M	0.00	0.00
Total Liabilities	72.18M	97.64M	226.83M	39.50M	7.12M	85.02M
Stockholders Equity	340.72M	428.68M	242.36M	212.55M	298.72M	-41.49M
Cash Flow
Free Cash Flow	-129.80M	-44.72M	134.19M	-96.67M	-55.44M	-27.89M
Operating Cash Flow	-127.91M	-41.56M	139.80M	-93.79M	-50.86M	-25.57M
Investing Cash Flow	141.05M	-27.80M	-138.40M	-148.65M	-4.58M	-2.32M
Financing Cash Flow	2.10M	102.96M	21.04M	479.00K	307.46M	50.09M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Positive. The current price of 6.91 is above the 20-day moving average (MA) of 6.59, above the 50-day MA of 5.96, and below the 200-day MA of 7.99, indicating a neutral trend. The MACD of 0.27 indicates Positive momentum. The RSI at 58.50 is Neutral, neither overbought nor oversold. The STOCH value of 55.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRDA	52 Neutral	$264.36M	―	-27.11%	―	-71.42%	-248.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GNFT	48 Neutral	$206.09M	-4.79	-51.06%	―	-44.94%	-274.42%
CCCC	47 Neutral	$221.50M	―	-59.98%	―	-10.57%	1.98%
SGMT	44 Neutral	$238.40M	―	-37.89%	―	-100.00%	-62.44%
VTYX	41 Neutral	$576.89M	-4.82	-48.56%	―	―	36.65%
BDTX	33 Underperform	$226.60M	10.72	19.23%	―	―	―

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics Reports Increased Losses Amid R&D Expansion

Entrada Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing innovative medicines that target intracellular mechanisms, primarily within the biotechnology sector. The company’s recent earnings report highlights a challenging quarter with a net loss of $44.1 million, reflecting increased research and development expenses as they advance their therapeutic programs. Key financial metrics indicate a decrease in collaboration revenue to $1.6 million for the quarter, down from $19.6 million the previous year, while operating expenses rose to $48.7 million. Despite these challenges, Entrada maintains a strong cash position with $326.8 million in cash, cash equivalents, and marketable securities, ensuring operational funding for at least the next twelve months. Looking ahead, the company remains focused on advancing its therapeutic candidates and leveraging its proprietary EEV platform to explore additional opportunities in the biopharmaceutical landscape.

Entrada Therapeutics Reports Q2 2025 Financial Results

Entrada Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing innovative therapies using its proprietary Endosomal Escape Vehicle (EEV) platform to target intracellular pathways. In its latest earnings report for the quarter ending June 30, 2025, Entrada Therapeutics highlighted a significant decrease in collaboration revenue compared to the previous year, alongside increased research and development expenses. The company reported a net loss of $43.1 million for the quarter, a stark contrast to the net income of $55 million in the same period last year. The company’s cash, cash equivalents, and marketable securities totaled $354 million, which is expected to support operations for the next twelve months. Despite the current financial challenges, Entrada remains committed to advancing its therapeutic candidates and leveraging its EEV platform to explore new opportunities in the biopharmaceutical sector.